Cubero-Gallego Hector, Calvo-Fernandez Alicia, Tizon-Marcos Helena, Aparisi Alvaro, Gomez-Lara Josep, Amat-Santos Ignacio, Fuertes Monica, Santos-Martinez Sandra, Salvatella Neus, Garcia-Guimaraes Marcos, Negrete Alejandro, Mohandes Mohsen, Gomez-Hospital Joan A, Moris Cesar, Vaquerizo Beatriz
Hospital del Mar (Parc de Salut Mar), Passeig Maritim 25-29, 08003 Barcelona, Spain.
J Invasive Cardiol. 2022 Oct;34(10):E701-E708. doi: 10.25270/jic/22.00058. Epub 2022 Aug 30.
Coronary lithotripsy (CL) works by fracturing the calcified plaque, allowing mean area gain, enhancing vessel compliance, and facilitating stent deployment. This study reports the safety, effectiveness, and durability of the clinical benefit of CL at long-term follow-up of a real-world multicenter registry.
This was a prospective, multicenter, single-arm study that included consecutive patients with calcified lesions undergoing CL from August, 2018 to October, 2020 with a clinical follow-up of 20 months (interquartile range, 14.5-25). Exclusion criteria were a target lesion located in a vessel <2.5 mm and/or the presence of dissection prior to CL. The primary endpoint was the rate of major adverse cardiovascular event (MACE, defined as death or target-lesion revascularization [TLR] or myocardial infarction [MI]) at follow-up.
This registry included 109 patients (128 lesions). The population was elderly (mean age, 74 years old), with high rates of diabetic patients (58%), renal insufficiency (32%), and multivessel disease (76%). Most of the lesions were predilated with semicompliant/noncompliant balloons (25 with cutting balloon). Rotational atherectomy was used in 20 lesions. On average, CL required the use of 1 balloon delivering a mean of 60 pulses. Twelve patients presented with ST-segment-elevation MI and a culprit calcified coronary lesion undergoing CL. Successful CL was achieved in 99% of cases. There were few procedural complications, with 30-day freedom from MACE rate of 98%. The MACE rate at long-term follow-up was 5.6%.
This is the first real-world, multicenter registry that confirms the safety and long-term efficacy of percutaneous coronary intervention for calcified lesions using CL in an unselected and high-risk population with a low long-term follow-up MACE rate.
冠状动脉旋磨术(CL)通过破碎钙化斑块发挥作用,可增加平均管腔面积、增强血管顺应性并便于支架置入。本研究报告了在一项真实世界多中心注册研究的长期随访中CL临床获益的安全性、有效性和持久性。
这是一项前瞻性、多中心、单臂研究,纳入了2018年8月至2020年10月期间连续接受CL治疗的钙化病变患者,临床随访20个月(四分位间距,14.5 - 25个月)。排除标准为靶病变位于直径<2.5 mm的血管以及/或CL术前存在夹层。主要终点是随访时主要不良心血管事件(MACE,定义为死亡或靶病变血运重建[TLR]或心肌梗死[MI])的发生率。
该注册研究纳入了109例患者(128处病变)。研究人群以老年人为主(平均年龄74岁),糖尿病患者比例高(58%),肾功能不全患者比例高(32%),多支血管病变患者比例高(76%)。大多数病变使用半顺应性/非顺应性球囊进行预扩张(25处使用切割球囊)。20处病变使用了旋切术。平均而言,CL需要使用1个球囊,平均输送60次脉冲。12例患者出现ST段抬高型心肌梗死且罪犯病变为钙化冠状动脉病变并接受了CL治疗。99%的病例成功完成CL。手术并发症较少,30天无MACE发生率为98%。长期随访时的MACE发生率为5.6%。
这是第一项真实世界、多中心注册研究,证实了在未选择的高危人群中使用CL进行经皮冠状动脉介入治疗钙化病变的安全性和长期疗效,长期随访时MACE发生率较低。